GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » Price-to-Free-Cash-Flow

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Price-to-Free-Cash-Flow : N/A (As of May. 28, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings Price-to-Free-Cash-Flow?

As of today (2024-05-28), Coeptis Therapeutics Holdings's share price is $0.2877. Coeptis Therapeutics Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.26. Hence, Coeptis Therapeutics Holdings's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Coeptis Therapeutics Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:

COEP's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.14
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Coeptis Therapeutics Holdings's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.05. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.26.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -22.60% per year.

During the past 4 years, Coeptis Therapeutics Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was -22.60% per year. The lowest was -22.60% per year. And the median was -22.60% per year.


Coeptis Therapeutics Holdings Price-to-Free-Cash-Flow Historical Data

The historical data trend for Coeptis Therapeutics Holdings's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coeptis Therapeutics Holdings Price-to-Free-Cash-Flow Chart

Coeptis Therapeutics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - -

Coeptis Therapeutics Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Coeptis Therapeutics Holdings's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coeptis Therapeutics Holdings's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's Price-to-Free-Cash-Flow falls into.



Coeptis Therapeutics Holdings Price-to-Free-Cash-Flow Calculation

Coeptis Therapeutics Holdings's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.2877/-0.264
=N/A

Coeptis Therapeutics Holdings's Share Price of today is $0.2877.
Coeptis Therapeutics Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Coeptis Therapeutics Holdings  (NAS:COEP) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Coeptis Therapeutics Holdings Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Executives
Tara Desilva director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick director, 10 percent owner, officer: CEO and President 5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind director 1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace director, officer: VP of Operations 402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise director, 10 percent owner, officer: Chief Financial Officer 801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps director 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy officer: CFO and Secretary 206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc 10 percent owner 299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr. 10 percent owner 151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp 10 percent owner 299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Headlines

From GuruFocus